INS and type 1 diabetes mellitus: In obese individuals with T1D and insufficient glycemic control, administration of liraglutide as an add-on to insulin for 24 weeks decreased body weight and insulin dose per day by 6.8 kg and 11.2 Units, respectively, while HbA1c was not improved more than in the placebo group.